Article Text

Download PDFPDF

21 Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients
  1. Michal Harel1,
  2. Coren Lahav1,
  3. Eyal Jacob1,
  4. Eran Issler1,
  5. Haim Bar2,
  6. Adam Dicker3,
  7. Ofer Sharon1,
  8. Antonietta Bacchiocchi4,
  9. Ruth Halaban4,
  10. Mario Sznol4 and
  11. Yuval Shaked5
  1. 1Oncohost LTD, Binyamina, Israel
  2. 2University of Connecticut, Storrs, CT, Israel
  3. 3Thomas Jefferson University, Philadelphia, PA, USA
  4. 4Yale University, New Haven, CT, USA
  5. 5Technion, Haifa, Israel


Background In recent years, studies have indicated that in response to almost any type of anti-cancer therapy, the patient (the host) may generate pro-tumorigenic and pro-metastatic effects. This phenomenon, called host-response, counteracts the anti-tumor activity of the treatment. We have previously shown that machine learning-based plasma proteomic analysis of the host response may serve as a predictive tool for response in non-small cell lung cancer. Here, we present initial results of a host response-based machine learning classifier that predicts clinical outcome in melanoma patients treated with immune checkpoint inhibitors (ICIs).

Methods Plasma samples from melanoma patients (training set; n=32) treated with anti-PD-1 or anti-PD-1 and anti-CTLA-4 combination were obtained at baseline and early on treatment. Response was based on RECIST criteria. Proteomic profiling of the plasma samples was performed using ELISA-based antibody arrays. Machine learning algorithms were used to identify a predictive signature that stratifies between responders and non-responders. The signature was validated on an independent cohort of melanoma patients (validation set; n=14). In addition, advanced bioinformatic analysis was performed in order to identify biological pathways unique to responders and non-responders.

Results A 3-protein signature was identified as a predictor of clinical outcome following immunotherapy with an area under the curve (AUC) of the receiver operating characteristics (ROC) plot of 0.88 (p-value 5.84E-05; confidence interval 0.76 – 1.0), and sensitivity and specificity of 0.65 and 0.95, respectively. This signature was successfully validated with AUC of 0.85 (p-value 0.03; confidence interval 0.63 – 1.0), and sensitivity and specificity of 0.75 and 0.9, respectively. To further explore the biological basis of resistance to immunotherapy, we performed a pathway enrichment analysis. Multiple mechanisms for resistance were identified in the non-responder group, including immunosuppression and inflammation associated pathways. Comparison between the two treatment modalities revealed pathways unique to each treatment that involve extracellular modulation, immunosuppression and processes associated with tumor progression, which may imply important differences between the two regimens.

Conclusions Our results demonstrate that analyzing the host response to ICI therapy using plasma-based proteomic profiling combined with machine learning algorithms serves as a successful approach for predictive biomarker discovery in melanoma. This bioinformatics-based functional analysis provides insights into mechanisms of resistance and may be used to identify potential strategies for improving clinical outcomes.

Ethics Approval The study was approved by the Yale University Institutional Review Ethics Board, approval number 0609001869.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.